2 results
Approved WMORecruiting
Primary(Part I and Part II):- To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) in the QW and/or Q3W regimens of RO7122290 in combination with cibisatamab after pretreatment with obinutuzumab- To characterize the…
Approved WMORecruiting
1.1 Primary study objectives To investigate the safety, tolerability and biochemical effects of 225Ac-PSMA injected in patients with metastatic prostate cancer. Primary objective:- To assess the safety and tolerability of 225Ac-PSMA administered…